

# Top Articles in Primary Care

John Russell  
Neil S. Skolnik  
*Editors*

 Springer

## Top Articles in Primary Care

John Russell • Neil S. Skolnik  
Editors

# Top Articles in Primary Care

 Springer

*Editors*

John Russell  
Family Medicine  
Jefferson Health  
Abington, PA, USA

Neil S. Skolnik  
Family Medicine  
Jefferson Health  
Abington, PA, USA

ISBN 978-3-031-25619-6      ISBN 978-3-031-25620-2 (eBook)  
<https://doi.org/10.1007/978-3-031-25620-2>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*John thanks*

*Elena, Dana, Erin and Paul*

*for all their love and support*

*Neil thanks*

*Alison, Aaron and Ava*

*who give life meaning, love and purpose*

*John and Neil would both like to thank*

*thirty years of residents who inspire our  
teaching*

*and who have taught us more than we  
taught them.*

*“We stand on the shoulders of giants”*

# Introduction

The two of us have worked together in the Abington Family Medicine Residency Program for over thirty years. During that time, we have learned more, argued more, joked more, and just had more fun together and with our colleagues than any two people should be allowed to have over the course of a career. All the time with unending respect for each other's intellect, empathy and humor.

We've taken care of patients and we've taught patient care.

Most relevant to this project, we've shared a love of ideas and the medical literature, and how that literature can be applied to patient care.

All of this is the backstory to this book—a love of the medical literature and a belief that an understanding and appreciation of that literature can enhance our lives as physicians, as well as the lives of our residents, students and patients.

We know that there is no one right answer to what are the top articles in primary care. All of us have our favorites, and inevitably there will be articles here that you will think should not have been included in such esteemed company, and you will have favorites that have been left out. This book will always be a work in progress, it has to be. There is a good chance that a new top article describing a critically important discovery for patients may come out next week. Don't hesitate to let us know if there is an article that you feel should be in here which was not, we'll seriously consider it for our next edition.

We want to take this opportunity to thank a hospital system that supports an academic community hospital family medicine residency and encourages intellectual pursuits, individual growth, innovation and learning.

We also want to thank seven very special individuals—the faculty at Abington Family Medicine—many of whom joined us in this project and with whom we daily share the joys and frustrations of academics, teaching and patient care—Gerald “Trip” Hansen, Mathew Clark, Amy Clouse, Tracey Roesing, Susan Kuchera Fidler, Meera Shah, and Bill Callahan.

Finally, we want to thank our families, who make it all worthwhile and who support us and put up with the sacrifices that a life in academic family medicine entails.

Deepest thanks, from John, to Elena, Dana, Erin, and Paul. Deepest thanks, from Neil, to Alison, Aaron and Ava. We (humbly) feel we have learned so much from each member of our family.

And...ok...thanks to each other.

~~Neil and John~~ John and Neil

# Contents

## Part I Behavioral Health

<b>1</b>	<b>Treatment Strategies in ADD-1999</b> .....	<b>3</b>
	Mackenzie Kramer	
<b>2</b>	<b>Cognitive Behavioral Therapy Versus Medications in Depression-2005</b> .....	<b>9</b>
	Christian Iversen	
<b>3</b>	<b>Treatment for Major Depressive Disorder (STAR*D)-2008</b> .....	<b>13</b>
	Aaron M. Sutton	
<b>4</b>	<b>Depression Screening Questions-2017</b> .....	<b>17</b>
	Carolyn Sciblo	

## Part II Cardiovascular Disease

<b>5</b>	<b>Pre-operative Clearance (Goldman Criteria)-1977</b> .....	<b>23</b>
	Shreeja Shah	
<b>6</b>	<b>Thrombolysis in Acute Strokes (ECASS-II)-1998</b> .....	<b>29</b>
	Patrick Ottman	
<b>7</b>	<b>Rate Versus Rhythm Control in Atrial Fibrillation (AFFIRM)-2002</b> .....	<b>33</b>
	Samantha P. Flanagan	
<b>8</b>	<b>Defibrillators in Low-Ejection Fraction Patients (MADIT-II)-2002</b> .....	<b>37</b>
	Binod Poudel	
<b>9</b>	<b>Medical Versus Interventional Management of Stable CAD (COURAGE)-2007</b> .....	<b>41</b>
	Anne Sprogell	

<b>10</b>	<b>Dabigatran Versus Warfarin in Atrial Fibrillation (RE-LY)-2009</b> .....	45
	Jeffrey Matthews	
<b>11</b>	<b>Aspirin and Clopidogrel in Transient Ischemic Attacks (CHANCE)-2013</b> .....	49
	Ifrah Naeem	
<b>12</b>	<b>Aspirin and Clopidogrel in High-Risk Transient Ischemic Attacks (POINT)-2018</b> .....	53
	Malik Muhammad Uzair Khan	
<b>13</b>	<b>Dapagliflozin in Low-EF Congestive Heart Failure (DAPA-HF)-2019</b> .....	57
	Lucy D. Checchio	
<b>14</b>	<b>Early Rhythm Control in Atrial Fibrillation (EAST)2020</b> .....	61
	Rameesha Mehreen	
<b>15</b>	<b>Empagliflozin in Diastolic Heart Failure (EMPEROR)-2021</b> .....	65
	Hamza Zahid Ullah Muhammadzai	
<b>Part III Diabetes</b>		
<b>16</b>	<b>Discovery of Insulin-1922</b> .....	71
	Alex Scott Fierstein	
<b>17</b>	<b>Diabetes Control and Outcomes (DCCT)-1993</b> .....	75
	Bhasha Mukhopadhyay	
<b>18</b>	<b>Lifestyle and Diabetes Prevention (DPP)-2002</b> .....	79
	Angela Kalinowski	
<b>19</b>	<b>Tight Control of Diabetes in Adult Patients (ACCORD)-2008</b> .....	83
	Juliana Carvajal and Gregory Palko	
<b>20</b>	<b>Blood Sugar Control in Intensive Care Patients (NICE SUGAR)-2009</b> .....	87
	Angela Kalinowski	
<b>21</b>	<b>Liraglutide and Cardiovascular Outcomes in Diabetes (LEADER)-2016</b> .....	91
	Gabriella Petrongolo	
<b>Part IV Hypertension</b>		
<b>22</b>	<b>Systolic Hypertension in the Elderly (SHEP)-1991</b> .....	97
	Bryce Eng and Meera Shah	
<b>23</b>	<b>Dietary Patterns in Hypertension (DASH)-1997</b> .....	101
	Morgan Katz	

**24 Comparison of Medications for Hypertension (ALLHAT)-2002** ..... 105  
 Nathaniel Rosal

**25 Intensive Versus Standard Blood Pressure Control (SPRINT)-2015** ..... 109  
 Alyssa J. Style

**26 Intensive BP Control in Older Patients (STEP)-2021** ..... 113  
 Stephanie Tzarnas

**Part V Infectious Disease**

**27 Penicillin for Strep Throat to Reduce Rheumatic Heart Disease-1950** ..... 119  
 Mathew Clark

**28 CDC’s Report of First Cases of AIDS in US-1981** ..... 123  
 Anne Sprogell and John Russell

**29 Decision for Hospital Admission for Community Acquired Pneumonia (PORT)-1997** ..... 127  
 Chris Azzolino

**30 Blood Testing for Diagnosis of Tuberculosis Infections-2006** ..... 131  
 Anne Sprogell

**31 Prophylaxis to Prevent HIV Infections (PREP)-2010** ..... 135  
 Dat Tran and William Callahan

**32 URI Prescription Management-2016** ..... 139  
 Angela Kalinowski

**Part VI Lipids**

**33 Lipid Lowering in Coronary Artery Disease (4S)-1994.** ..... 145  
 Anupriya Grover-Wenk

**34 Intensive Versus Moderate Lipid Lowering for Acute Coronary Syndrome-2004.** ..... 149  
 Evan R. Gooberman

**35 Preventing Vascular Events with Rosuvastatin in Patients with Elevated CRP (JUPITER)-2008.** ..... 153  
 Angela Kalinowski

**36 Adding Niacin to Statin Therapy in CAD (AIM-HIGH)-2011** ..... 157  
 Thomas McGinley

<b>37</b>	<b>Novel Non Statin Therapy for Hyperlipidemia-PCSK9-2018</b> .....	161
	Katherine Fradeneck, Merna Mikhail, and Robert Danoff	
<b>38</b>	<b>Icosapent Ethyl for Elevated Triglycerides2019</b> .....	165
	Diana Bonaccorsi and Danielle Carcia	
<b>Part VII Nephrology</b>		
<b>39</b>	<b>ACE Inhibitors Impact on Slowing the Progression of Diabetic Nephropathy-1993</b> .....	171
	Tina Chuong	
<b>40</b>	<b>ARB and the Slowing of Progression of Diabetic Nephropathy 2001</b> .....	175
	Sharon Buchbinder	
<b>41</b>	<b>SGLT2 Inhibitors and Diabetic Renal Protection-2020</b> .....	179
	Evan R. Gooberman	
<b>42</b>	<b>Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes-2020</b> .....	183
	Rui Song	
<b>Part VIII Obesity</b>		
<b>43</b>	<b>Phen/Fen for Weight Loss-1984</b> .....	189
	Angela Kalinowski	
<b>44</b>	<b>Semaglutide in Obesity (STEP-1 Trial)-2021</b> .....	193
	Samantha P. Flanagan	
<b>45</b>	<b>Carbohydrate-Insulin Model for Obesity-2021</b> .....	197
	Samantha P. Flanagan	
<b>46</b>	<b>Tirzepatide for Obesity-2022</b> .....	201
	Christian Iversen	
<b>Part IX Orthopaedics</b>		
<b>47</b>	<b>Signs of Non-organic Back Pain-1980</b> .....	207
	Bree Zeyzus Johns	
<b>48</b>	<b>Ottawa Ankle Rules-X-Rays in Ankle Injuries-1992</b> .....	211
	Sean P. Carnahan	
<b>49</b>	<b>Arthroscopic Surgery in Osteoarthritis-2002</b> .....	215
	Dimitry Belogorodsky	
<b>50</b>	<b>Exercise Prescriptions-2011</b> .....	219
	Bridget Smith	

**51 Early Exercise in Concussions-2019** ..... 223  
Kevin Franco

**Part X Other Areas of Medicine**

**52 The Framework for Medical Records-1968** ..... 229  
Susan Kuchera Fidler

**53 Establishing a Biopsychosocial Framework  
for Medicine-1977** ..... 233  
Sophie K. Oh

**54 Alpha Blockers and Finasteride for BPH-1996** ..... 237  
Kevin Franco

**55 Sildenafil for Erectile Dysfunction-1998**..... 241  
Karen Lazarus

**56 A Randomized Trial Comparing Conventional and  
Endovascular Repair of Abdominal Aortic Aneurysms-2008**..... 245  
Marissa Norden

**Part XI Pediatrics**

**57 Sleeping Position and SIDS-1993**..... 251  
Gerard Cleary and Sean Cleary

**58 MMR and Autism 1998**..... 259  
Christian Iversen

**Part XII Pharmacology**

**59 Vitamin C and the Prevention of Respiratory Infections-1974**..... 265  
John Russell

**60 The Porter Letter: The Link between Long-Term  
Opioids and Addiction-1980**..... 269  
Erin Russell and John Russell

**61 Antioxidants and Macular Degeneration-2001** ..... 273  
Anne Sprogell

**Part XIII Preventive Medicine**

**62 Periodic Health Screening-1975**..... 279  
Mathew Clark

**63 Fitness and Coronary Artery Disease-2004** ..... 283  
Carolyn Sciblo

**64 Smoking and Risk of Lung Cancer: A 50 Year Evaluation-2004.** . . . . . 287  
Jonathan P. Andrews

**Part XIV Pulmonary**

**65 Adding LABA to Asthma Therapy (SMART)-2006.** . . . . . 293  
Marie Madden

**66 Long-acting Beta-agonist Plus Inhaled Corticosteroid in COPD (TORCH)-2007** . . . . . 297  
Jeffrey Matthews

**67 Once-Daily Single-Inhaler Triple vs Dual Therapy in Patients with COPD-2018.** . . . . . 301  
Tricia Cavanaugh

**68 As Needed LABA/ICS in Asthma (START)-2019** . . . . . 305  
Carrie L. Bender

**69 Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD-2020.** . . . . . 309  
Tricia Cavanaugh

**Part XV Women’s Health**

**70 Introduction of Combined Hormonal Oral Contraceptives-1958** . . . . . 315  
Amy Clouse

**71 Folic Acid to Reduce Neural Tube Defects-1992** . . . . . 319  
Anne Sprogell

**72 AZT Treatment to Prevent Maternal-Infant Transmission of HIV-1994** . . . . . 323  
Bhasha Mukhopadhyay

**73 Coronary Heart Disease and HRT (HERS Trial)-1998.** . . . . . 327  
Kathleen E. Leary

**74 Endometrial Sampling Accuracy 2000** . . . . . 331  
Morgan Katz

**75 HPV-16 Vaccine-2002** . . . . . 335  
Dyllan Walter

**76 Risks and Benefits of Estrogen/Progestin in Healthy Women (WHI)-2002** . . . . . 339  
Aarisha Shrestha

**Index.** . . . . . 343

# Contributors

- Jonathan P. Andrews** Jefferson Health, Abington, PA, USA  
**Chris Azzolino** Jefferson Health, Abington, PA, USA  
**Dimitry Belogorodsky** Jefferson Health, Abington, PA, USA  
**Carrie L. Bender, DO** Jefferson Health, Abington, PA, USA  
**Diana Bonaccorsi** Capital Health, Trenton, NJ, USA  
**Sharon Buchbinder** Jefferson Health, Abington, PA, USA  
**William Callahan** Jefferson Health, Abington, PA, USA  
**Danielle Carcia** Capital Health, Trenton, NJ, USA  
**Sean P. Carnahan** UPMC, Pittsburgh, PA, USA  
**Juliana Carvajal** Jefferson Health, Abington, PA, USA  
**Tricia Cavanaugh** Jefferson Health, Abington, PA, USA  
**Lucy D. Checchio** Jefferson Health, Abington, PA, USA  
**Tina Chuong** Jefferson Health, Abington, PA, USA  
**Mathew Clark** Jefferson Health, Abington, PA, USA  
**Gerard Cleary** Jefferson Health, Abington, PA, USA  
**Sean Cleary** Jefferson Health, Abington, PA, USA  
Philadelphia College of Osteopathic Medicine, PCOM, Philadelphia, PA, USA  
**Amy Clouse, MD** Jefferson Health, Abington, PA, USA  
**Robert Danoff** Jefferson Health Northeast, Philadelphia, PA, USA  
**Bryce Eng** Jefferson Health, Abington, PA, USA  
**Susan Kuchera Fidler** Jefferson Health, Abington, PA, USA

- Alex Scott Fierstein** Jefferson Health, Abington, PA, USA
- Samantha P. Flanagan, DO** Main Line Health, King of Prussia, PA, USA
- Katherine Fradeneck** Jefferson Health Northeast, Philadelphia, PA, USA
- Kevin Franco** Jefferson Health, Abington, PA, USA
- Evan R. Gooberman** Jefferson Health, Abington, PA, USA
- Anupriya Grover-Wenk** Jefferson Health, Abington, PA, USA
- Christian Iversen** Jefferson Health, Abington, PA, USA
- Angela Kalinowski** Jefferson Health, Abington, PA, USA
- Morgan Katz** Jefferson Health, Abington, PA, USA  
Primary Care, ChristianaCare, Newark, USA
- Malik Muhammad Uzair Khan** Jefferson Health, Abington, PA, USA
- Mackenzie Kramer** Jefferson Health, Abington, PA, USA
- Karen Lazarus** Jefferson Health, Abington, PA, USA
- Kathleen E. Leary** Jefferson Health, Abington, PA, USA
- Marie Madden** Jefferson Health, Abington, PA, USA
- Jeffrey Matthews** Jefferson Health, Abington, PA, USA
- Thomas McGinley** St. Luke's Health, Coaldale, PA, USA
- Rameesha Mehreen** Jefferson Health, Abington, PA, USA
- Merna Mikhail** Jefferson Health Northeast, Philadelphia, PA, USA
- Hamza Zahid Ullah Muhammadzai** Jefferson Health, Abington, PA, USA
- Bhasha Mukhopadhyay** Jefferson Health Abington, Abington, PA, USA
- Ifrah Naeem** Jefferson Health, Abington, PA, USA
- Marissa Norden** Jefferson Health, Abington, PA, USA
- Sophie K. Oh** Jefferson Health, Abington, PA, USA
- Patrick Ottman** Jefferson Health, Abington, PA, USA
- Gregory Palko** Jefferson Health, Abington, PA, USA
- Gabriella Petrongolo** Jefferson Health, Abington, PA, USA
- Binod Poudel** Jefferson Health, Abington, PA, USA
- Nathaniel Rosal, DO** Jefferson Health, Abington, PA, USA

**Erin Russell** Temple University School of Medicine, Philadelphia, PA, USA  
Jefferson Health, Abington, PA, USA

**John Russell** Jefferson Health, Abington, PA, USA  
Family Medicine, Jefferson Health, Philadelphia, PA, USA

**Carolyn Sciblo** Temple Health Chestnut Hill Family Medicine,  
Philadelphia, PA, USA

**Meera Shah** Jefferson Health, Abington, PA, USA

**Shreeja Shah** Jefferson Health, Abington, PA, USA

**Aarisha Shrestha, DO** Jefferson Health, Abington, PA, USA

**Bridget Smith** Jefferson Health, Abington, PA, USA

**Rui Song** Jefferson Health, Abington, PA, USA

**Anne Sprogell** Jefferson Health, Abington, PA, USA

**Alyssa J. Style** Jefferson Health, Abington, PA, USA

**Aaron M. Sutton, LCSW, BCD, CAADC** Jefferson Health, Abington, PA, USA

**Dat Tran** Jefferson Health, Abington, PA, USA

**Stephanie Tzarnas, MD** Jefferson Health, Abington, PA, USA

**Dyllan Walter** Jefferson Health, Abington, PA, USA

**Bree Zeyzus Johns** Jefferson Health, Abington, PA, USA

# **Part I**

# **Behavioral Health**

**Aaron Sutton**

# Chapter 1

## Treatment Strategies in ADD-1999



Mackenzie Kramer

### Background

Attention-deficit hyperactivity disorder (ADHD) is defined by the DSM-V as a persistent pattern of inattention and/or hyperactivity/impulsivity that interferes with functioning and development [1]. ADHD is the most common psychiatric disorder in childhood, affecting 3–5% of school aged children and accounting for 30–50% of child referrals to mental health services [2, 3]. Previous studies have showed the efficacy of short-term treatments of both pharmacotherapy and behavior therapy in treating symptoms of ADHD; however, few controlled studies have followed participants for greater than four months. At the time this study was undertaken, there was a great deal of public concern over the use of stimulants in children with ADHD given the lack of evidence to show that they are effective. This study, the Multimodal Treatment Study of Children With ADHD (MTA), aimed to evaluate pharmacotherapy, behavior therapy, and a combination of the two in a longer-term clinical trial.

---

The MTA Cooperative Group. A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity Disorder. *Arch Gen Psychiatry*. 1999;56(12):1073–1086. doi:10.1001/archpsyc.56.12.1073. <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/205525>

---

M. Kramer (✉)  
Jefferson Health, Abington, PA, USA  
e-mail: [Mackenzie.kramer@jefferson.edu](mailto:Mackenzie.kramer@jefferson.edu)

## Objective

- To see how long-term medication and behavioral treatments compare with one another when treating children with ADHD, and if there is an additional advantage to using these treatment modalities in combination.
- To evaluate the effectiveness of carefully delivered treatments against routine community care.

## Design and Methods

- The study included 579 children, aged 7–9.9 years, with ADHD Combined Type who were randomly assigned to one of the four treatment groups for 14 months.
- Outcomes were measured in distinct groups rated by parents and teachers: primary ADHD symptoms, aggressive and oppositional behavior, internalizing symptoms, for example, anxiety and sadness, social skills, parent–child relationship, and academic achievement.
- Treatment groups included intensive medication management alone, intensive behavioral treatment alone, a combination of both, and routine community care (the control group).
- Behavioral treatment included parent, school, and child components with therapist involvement that gradually reduced over time.
- Medication management was with methylphenidate hydrochloride. If adequate response to methylphenidate was not obtained during titration, alternate medications were titrated openly in the order until a satisfactory response was found: dextroamphetamine, pemoline, imipramine, and, if necessary, others approved by a cross-site panel. Eighty-nine percent completed titration of medication; of these, Sixty-nine percent were assigned to an individually titrated dose of methylphenidate, with average initial doses of 30.5 mg/d. The remaining subjects were openly titrated to dextroamphetamine due to inadequate response to methylphenidate.
- Standard community care involved treatment by community providers. It should be noted that the community care group included many children who received medication and behavioral therapy, since a placebo group with no intervention would have been unethical for this disorder over this period of time.
- Data was analyzed by intent-to-treat random-effects regression procedures over a course of 14 months.

## Results

- All 4 groups showed sizable reduction in ADHD symptoms over time, with significant differences between the groups in the degree of improvement.

- Medication management alone, when compared to behavioral treatment alone, showed significant improvements in primary ADHD symptoms, including inattention and hyperactivity-impulsivity, rated by parents and teachers. According to the authors, “Robust differences were found according to 2 different data sources, indicating the superiority of medication management over behavioral treatment for ADHD symptoms.”
- When comparing other areas of children’s functioning including aggressive and oppositional behavior, peer relations, and academic achievement, medication management alone showed no significant benefit when compared to behavioral treatment alone.
- Children in the combined treatment group and the medication management group showed significant improvement compared to those in the behavioral treatment group as well as the control group. Combined treatment and medication management did not differ significantly across any domain.
- Combined treatment and medication management were superior to community care for parent- and teacher-reported ADHD symptoms. Behavioral treatment showed no significant benefit compared to community care.

## Importance

ADHD is the most common psychiatric disorder in childhood and has now been seen to persist into adulthood. This study was the first of its kind to evaluate the differences between pharmacotherapy, behavioral therapy, and a combination of the two in a longer-term clinical trial. While all groups showed a reduction in ADHD symptoms over time, there were important benefits to medication, as well as combined medication and behavioral treatment, with no significant effect of behavioral treatment alone. The MTA updates, which are published approximately every 2 years, give us an insight into more long-term health effects of medication, efficacy, and more research that needs to be done.

## Updates

- The MTA was designed and conducted in the early 1990s and underwent eight assessments from the baseline data, published every 2 years.
- In 2007, the MTA published a follow-up following 485 of the original 579 children. Among children who continued to take the ADHD medication consistently, the stimulants started to lose effectiveness around three years after treatment was started [2].
- At the 16-year follow up, it was concluded that more than 60% of children, regardless of their medication use, continued to show ADHD symptoms into adulthood [4, 5].

- Multiple studies have shown strong evidence for decreased height associated with prolonged psychostimulant medication taken consistently compared to those who stopped stimulant medication or took it sporadically<sup>5</sup>.

## Bottom Line

- While all four groups showed improvement over time medication management and combined medication and behavioral therapy were superior to behavioral treatment or community treatment in reducing ADHD symptoms.
- Combined treatment was not better than medication alone for reducing core symptoms of ADHD.
- The authors point out the lack of efficacy of behavioral treatments on the core ADHD symptoms does not mean that behavioral therapy is not important and does not help critical domains of function. ADHD is a chronic disease, the manifestations of which wax and wane over time, often depending upon demands and stressors. Behavioral therapy has value in helping to function optimally given those many issues.
- The original data published in 1999, as well as the extensive follow-up data over the following 16 years, show that an optimal dose of stimulant medication provides children with ADHD an effective way to improve symptoms; however, over time, the medication loses effectiveness.
- The MTA findings challenged the notion that 50% of children with ADHD outgrow the disorder in adulthood. Although intermittent periods of remissions can be expected, approximately 90% of participants in the MTA trial experienced residual ADHD symptoms in young adulthood [6].
- Clinicians must work with their patients to develop an individualized plan for treatment of ADHD and carefully monitor medication prescribed at the correct dose while utilizing other interventions including behavioral therapy.

## References

1. Attention-Deficit/Hyperactivity Disorder. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2013.
2. “The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study (Mta): Questions and Answers.” National Institute of Mental Health, U.S. Department of Health and Human Services, [https://www.nimh.nih.gov/funding/clinical\\_research/practical/mta/the-multimodal-treatment-of-attention-deficit-hyperactivity-disorder-study-mtaquestions-and-answers](https://www.nimh.nih.gov/funding/clinical_research/practical/mta/the-multimodal-treatment-of-attention-deficit-hyperactivity-disorder-study-mtaquestions-and-answers).
3. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–86. <https://doi.org/10.1001/archpsyc.56.12.1073>.

4. Hechtman L, Swanson JM, Sibley MH, Stehli A, Owens EB, Mitchell JT, Arnold LE, Molina BS, Hinshaw SP, Jensen PS, Abikoff HB, Perez Algorta G, Howard AL, Hoza B, Etcovitch J, Houssais S, Lakes KD, Nichols JQ, MTA Cooperative Group. Functional adult outcomes 16 years after childhood diagnosis of attention-deficit/hyperactivity disorder: MTA results. *J Am Acad Child Adolesc Psychiatry*. 2016;55(11):945–952.e2. <https://doi.org/10.1016/j.jaac.2016.07.774>.
5. Editorial: The Continuing Contributions of MTA over Nearly Two Decades to Initial <https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/jcpp.12755>.
6. Sibley MH, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. *Am J Psychiatr*. 2022;179(2):142–51. <https://doi.org/10.1176/appi.ajp.2021.21010032>.

# Chapter 2

## Cognitive Behavioral Therapy Versus Medications in Depression-2005



Christian Iversen

### Background

Both medications and cognitive therapy had shown efficacy in treatment of depression, including a large study by the Treatment of Depression Collaborative Research Program (TDCRP). This research demonstrated medications were superior to cognitive therapy for severe depression which became the standard of care recommended by the American Psychiatric Association. Prior to this study, there was no randomized, placebo-controlled comparison of medication and cognitive therapy for treatment of moderate to severe depression.

### Objective

- To compare efficacy of antidepressant medication and cognitive therapy for treatment of moderate to severe depression.

---

DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O'Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., & Gallop, R. (2005). Cognitive therapy vs medications in the treatment of moderate to severe depression. *Archives of general psychiatry*, 62(4), 409–416. <https://doi.org/10.1001/archpsyc.62.4.409>. <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/208460>

---

C. Iversen (✉)  
Jefferson Health, Abington, PA, USA  
e-mail: [christian.iversen@jefferson.edu](mailto:christian.iversen@jefferson.edu)

## Design and Methods

- Participants had a diagnosis of major depressive disorder according to DSM IV, were 18–70 years old, spoke English, and could provide informed consent.
- Patients were assessed by the 17-question Hamilton Depression Rating Scale (HDRS) modified to account for both typical and atypical presentations of depression. Patients were required to score 20 or more on two occasions separated by 7 days, and diagnosis was confirmed by a psychiatrist.
- Eligible patients were randomly assigned to medication ( $n = 120$ ), placebo pill ( $n = 60$ ), or cognitive therapy ( $n = 60$ ). Placebo pills were only used for 8 weeks. The medication group was larger to allow additional randomization at the conclusion of this study to assess relapse [1].
- Pharmacology group (paroxetine and placebo pill):
  - Pharmacotherapy sessions conducted by psychiatrists to discuss medications and provide limited supportive counseling. Cognitive therapy techniques were prohibited.
  - Paroxetine doses started at 10–20 mg/day and increased to maximum of 50 mg/day.
  - Patients who failed to respond to paroxetine by 8 weeks were offered additional treatment.
  - Blinding for patients and psychiatrists of the placebo group was broken at 8 weeks, and treatment was offered.
- Cognitive therapy group:
  - Psychologists and a psychiatric nurse practitioner conducted cognitive therapy sessions.
  - Patients were initially treated with 50-min sessions biweekly for 4 weeks with progression to weekly sessions over the subsequent 12 weeks.
- Outcome analysis:
  - The primary endpoint was HDRS reduction at 8 and 16 weeks, with response indicated by a score of 12 or less and stable or decreasing levels at the end of the study.
  - Full remission was defined as HDRS of 7 or less.

## Results

- There was nearly equivalent attrition in both medication and cognitive therapy groups. Notably, 5% of the medication group stopped due to side effects or worsening symptoms; approximately 7% stopped therapy for dissatisfaction.
- Paroxetine dose started at  $14.0 \pm 4.9$  mg rising to  $37.3 \pm 12.4$  mg at the end of 16 weeks.

- 47 patients (39%) required augmentation of therapy with lithium, desipramine, venlafaxine, or some combination thereof due to insufficient response on HDRS.
- Both medication and cognitive therapy outperformed placebo to a statistically significant level at 8 weeks. At this point, placebo treatment was discontinued.
- There was no statistically significant difference between medication and cognitive therapy for response rates at 8 or 16 weeks, or for remission at 16 weeks.
- There was evidence that patients with comorbid anxiety responded better to medication, “perhaps because paroxetine [...] has anxiolytic effects”.
- There was additional evidence that cognitive therapy at Pennsylvania was more effective than Vanderbilt, “likely related to therapist experience”.

## Importance

Similar efficacy was demonstrated for both cognitive therapy and medication for symptomatic improvement and remission of moderate to severe depression in this randomized, placebo-controlled trial. Both treatments were superior to placebo pill. This study provided additional evidence for the therapeutic value of both cognitive therapy and medication management of depression.

## Updates

- Patients were followed to assess rates of relapse following completion of the above study [1]. Patients withdrawn from cognitive therapy were less likely to relapse compared with those withdrawn from medication. There was no statistical difference between those withdrawn from therapy and those continuing medication.
- The American Psychiatric Association (APA) recommends second generation antidepressants (SSRI or SNRI), cognitive therapy, or a combination thereof for initial treatment of depression in adults [2]. They additionally suggest cognitive therapy to prevent relapse following remission.

## Bottom Line

- Both medication and cognitive therapy provided therapeutic benefit for patients experiencing moderate to severe depression. Relapse was more common following discontinuation of medication compared with therapy. Importantly, therapist experience likely influenced outcomes.

## References

1. Hollon S, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. *Arch Gen Psychiatry*. 2005;62(4):417–22.
2. American Psychological Association. (2019). Clinical practice guideline for the treatment of depression across three age cohorts. Retrieved from <https://www.apa.org/depression-guideline>

# Chapter 3

## Treatment for Major Depressive Disorder (STAR\*D)-2008



Aaron M. Sutton

### Background

Depression affects approximately 1 in 8 Americans and is the second leading cause of disability-adjusted life years in those 15–44 years old [1]. The majority of individuals with major depressive disorder (MDD) have a chronic or recurrent course and many continue to have symptoms and periods of disability between episodes [2]. Prior to the Sequenced Treatment Alternative to Relieve Depression (STAR\*D) trial, there was little evidence in regard to treating patients in real world settings. The majority of previous trials included participants who were recruited through advertisement and who often had few medical or psychiatric comorbidities. In addition, though there had been many trials of the effectiveness of antidepressants in patients with MDD, there was not much evidence about additional anti-depressive treatment that is often needed for the large proportion of patients (up to two-third of patients) who do not respond, or have only a partial response, to first line treatment.

---

Warden, Diane & Rush, Augustus & Trivedi, Madhukar & Fava, Maurizio & Wisniewski, Stephen. (2008). The STAR\*D Project results: A comprehensive review of findings. *Current psychiatry reports*. 9. 449-59. 10.1007/s11920-007-0061-3. <https://link.springer.com/article/10.1007/s11920-007-0061-3>

---

A. M. Sutton (✉)  
Jefferson Health, Abington, PA, USA  
e-mail: [aaron.sutton@jefferson.edu](mailto:aaron.sutton@jefferson.edu)

## Objective

The STAR\*D trial aimed to develop treatment strategies that would improve clinical outcomes in patients with treatment resistant depression, who were experiencing a major depressive episode. Specifically, the trial focused on how to initiate treatment and what the next steps in treatment would be, should participants not reach remission or cannot tolerate the treatment.

## Design and Methods

- Over a 7-year period, 4041 outpatients between 18 and 75 years of age were enrolled from 41 clinical sites across the country; 2876 were eligible and began level 1. Level 2 results included 1439, level 3 included 377, and level 4 included 142.
- In level 1, participants were given citalopram (Celexa) for 12–14 weeks. If patients became symptom free, they could move to a 12-month follow-up program in which Celexa was continued and patients were monitored. If participants could not tolerate Celexa, or did not become symptom free, they moved to level 2.
- Participants in level 2 had the option of switching medication or adding medication to Celexa. Those who switched were randomly assigned either sertraline (Zoloft), bupropion-SR (Wellbutrin), or Venlafaxine XR (Effexor). If augmenting, participants were randomly assigned bupropion-SR (Wellbutrin) or buspirone to continue with Celexa. Participants also had the option of adding on or switching to cognitive therapy. As in level 1, if participants became symptom free, they would continue with treatment and those who did not or could not tolerate treatment moved to level 3.
- Level 3, like level 2, allowed participants the opportunity to switch or augment. If switching, participants were randomly assigned either mirtazapine (Remeron) or nortriptyline (Aventyl or Pamelor) for up to 14 weeks. In the augmentation group, participants were randomly assigned to lithium or triiodothyronine (T3). As in previous levels, if participants became symptom free, they would be monitored and those who did not or could not tolerate medications proceeded to level 4.
- Participants in level 4 were taken off any previous medications and randomly switched to either the monoamine oxidase inhibitor (MAOI) tranylcypromine (Parnate) or the combination of venlafaxine extended release (Effexor XR) with mirtazapine (Remeron).

## Results

- The majority of clinical trials for depression use a measure of success called “response,” which means that symptoms have decreased to at least half of what they were when starting a trial. However, the STAR\*D trial uses the measure of remission, meaning that participants were symptom free, however notes response as well.
- In level 1, remission rates were between 28 and 33% with further response rate between 10 and 15% depending on what measurement was used for assessment, either the Hamilton Depression Rating Scale (HDRS) or Quick Inventory for Depression Screening (QIDS).
- At level 2, patients who did not have a full response to citalopram were switched to either bupropion-SR, sertraline, and venlafaxine-XR. About one-fourth of patients who had a medication switch experienced a remission, and remission rates for bupropion-SR, sertraline, and venlafaxine-XR were similar.
- At level 2 patients could choose augmentation with bupropion-SR or buspirone. Patients treated with bupropion-SR showed greater symptom improvement, lower symptom severity, and fewer dropouts due to intolerance.
- Cognitive therapy had equal efficacy when used as a level 2 augmentation strategy as when medication was used to augment citalopram. When used as “switch therapy,” i.e., when patients stopped their level 1 citalopram therapy and switched to either a different medicine or cognitive therapy, a fourth of patients had equal efficacy to switching medications, with approximately a fourth of patients in both groups showing a response.
- Level 3 remission rates varied between switching to mirtazapine (12%) and augmentation with triiodothyronine or T3 (25%). Again, there were no statistically significant differences in medications used.
- In level 4, the remission rate from switching to tranylcypromine was 7%, while the combination of venlafaxine extended release (Effexor XR) with mirtazapine (Remeron) was 14%.

## Importance

With an estimated 16 million Americans experiencing a depressive episode in a given year, family physicians are on the front line of providing care. Currently, general practitioners prescribe about 60% of all psychotropic medications with family medicine physicians being a majority in that group [3]. It is important to understand all treatment options including how to initiate treatment, augmenting treatment, providing options and rationale for psychotherapy, and discussing expectations for treatment with patients.

## Updates

- Multiple articles have been published since the results of STAR\*D were published asking for further evaluation of results based on biases. Potential detriments to the study include “treat to remission method,” overstated estimates of remission, acknowledgement of participants that dropped out through step 3, and an assumption that those who dropped out could be included in the group that was successfully treated [4].

## Bottom Line

- Primary care physicians can effectively treat depression in a primary care “real world” setting. Many patients who do not achieve remission or response after a few weeks typically do so after 14 weeks. If initial treatment with an SSRI does not lead to full remission, the evidence supports additional therapeutic approaches. The therapeutic approach can be effective in leading to remission either by switching to a different anti-depressant, or by augmenting the initial treatment with bupropion-SR. Cognitive therapy had efficacy equal to medication as second level therapy either by switching to cognitive therapy or augmenting the existent medication with cognitive therapy.

## References

1. Indian J Psychol Med. 2010;32(1):1–2.
2. Bains N, Abdijadid S. Major Depressive Disorder. [Updated 2022 Jun 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
3. Barkil-Oteo A. Collaborative care for depression in primary care: how psychiatry could “troubleshoot” current treatments and practices. *Yale J Biol Med.* 2013;86(2):139–46. PMID: 23766735; PMCID: PMC3670434.
4. Pigott HE. The STAR\*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. *Can J Psychiatry.* 2015;60(1):9–13. <https://doi.org/10.1177/070674371506000104>. PMID: 25886544; PMCID: PMC4314062.